Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 455-463

  Castaneda, Carlos ^a   Meadows, Kellen L ^b   Truax, Roxanne ^b   Morse, Michael A ^b   Kaufmann, Scott H ^c   Petros, William P ^d   Zhu, Yali ^e   Statkevich, Paul ^e   Cutler, David L ^e   Hurwitz, Herbert I ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^b DUKE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Advanced solid tumors; Lonafarnib; Pharmacokinetics; Phase I; SCH 66336

Indexed keywords

LONAFARNIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NUCLEAR PROTEIN; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; PIPERIDINE DERIVATIVE; PRELAMIN A; PROTEIN PRECURSOR; PYRIDINE DERIVATIVE; TRANSFERASE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; MORTALITY; MOUTH MUCOSA; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASMS; NUCLEAR PROTEINS; PIPERIDINES; PROTEIN PRECURSORS; PYRIDINES; TREATMENT OUTCOME;

EID: 79953791317     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1488-5     Document Type: Article

References (41)

1. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. The Journal of biological chemistry 280:31101-31108 (Pubitemid 41291845)
2. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689 (Pubitemid 19213607)
3. Sebti SM, Adjei AA (2004) Farnesyltransferase inhibitors. Semin Oncol 31:28-39 (Pubitemid 38241018)
4. Ashar HR, Armstrong L, James LJ, Carr DM, Gray K, Taveras A, Doll RJ, Bishop WR, Kirschmeier PT (2000) Biological effects and mechanism of action of farnesyl transferase inhibitors. Chem Res Toxicol 13:949-952
5. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. The Journal of biological chemistry 275:30451-30457
6. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao y (2004) A tagging-viasubstrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences of the United States of America 101:12479-12484 (Pubitemid 39122049)
7. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997) Farnesyltransferase inhibitors alter the prenylation and growthstimulating function of RhoB. The Journal of biological chemistry 272:15591-15594 (Pubitemid 27265524)
8. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR (1997) Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. The Journal of biological chemistry 272:10232-10239 (Pubitemid 27171703)
9. Hancock JF, Cadwallader K, Paterson H, Marshall CJ (1991) A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. The EMBO journal 10:4033-4039 (Pubitemid 21905433)
10. Hancock JF, Paterson H, Marshall CJ (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63:133-139
11. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proceedings of the National Academy of Sciences of the United States of America 89:6403-6407
12. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63:5656-5668 (Pubitemid 37187458)
13. James GL, Goldstein JL, Brown MS (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. The Journal of biological chemistry 270:6221-6226
14. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. The Journal of biological chemistry 272:14459-14464 (Pubitemid 27232866)
15. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM (1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. The Journal of biological chemistry 272:14093-14097 (Pubitemid 27232813)
16. Sun J, Qian Y, Hamilton AD, Sebti SM (1998) Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473 (Pubitemid 28151853)
17. Cox AD, der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333: F51-F71 (Pubitemid 27359966)
18. Lebowitz PF, Prendergast GC (1998) Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17:1439-1445 (Pubitemid 28458411)
19. Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, de Silva H, Franke Y, Guan B, Heuer T, Hung T, Keegan K, Lee JM, Manne V, O'Brien C, Parry D, Perez-Villar JJ, Reddy RK, Xiao H, Zhan H, Cockett M, Plowman G, Fitzgerald K, Costa M, Ross-Macdonald P (2005) Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7:325-336 (Pubitemid 40544650)
20. Pan J, Yeung SC (2005) Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 65:9109-9112 (Pubitemid 41507967)
21. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7:1438-1445 (Pubitemid 32708700)
22. Feldkamp MM, Lau N, Roncari L, Guha A (2001) Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 61:4425-4431 (Pubitemid 32685770)
23. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR et al (1998) Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58:4947-4956 (Pubitemid 28503695)
24. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ (2001) Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-1412 (Pubitemid 32183766)
25. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S, Von Hoff DD (1999) Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol 10:449-453 (Pubitemid 29236423)
26. Reichert A, Heisterkamp N, Daley GQ, Groffen J (2001) Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97:1399-1403 (Pubitemid 32183765)
27. National Institutes of Health (1982) Common terminology criteria for adverse events
28. Schering-Plough Corporation (1997) SCH 66336: Investigator's Brochure information for the investigational product. Schering-Plough Research Institute, Kenilworth
29. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
30. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000) Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6:2318-2325 (Pubitemid 30399198)
31. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH (2000) A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60:1871-1877 (Pubitemid 30207646)
32. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J (2002) Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38:2272-2278 (Pubitemid 35346469)
33. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M (2001) Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19:1167-1175 (Pubitemid 32176295)
34. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H (2007) Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110:1295-1302 (Pubitemid 47435601)
35. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK (2004) Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10:2968-2976 (Pubitemid 38619672)
36. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun le (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 25:3137-3143 (Pubitemid 47218063)
37. Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM (2007) Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 13:576-583 (Pubitemid 46225364)
38. Clinical Trials. gov. National Institutes of Health
39. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES (2009) A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 32:274-279
40. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR (2005) Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104:561-569 (Pubitemid 41022814)
41. Ravoet C, Mineur P, Robin V, Debusscher L, Bosly A, Andre M, El Housni H, Soree A, Bron D, Martiat P (2008) Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 87:881-885